RxDoctor Payments Data

Nashib Hashmi, MD

Nephrology · Kankakee, ILNPI 1629194543

Payments from drug & device makers

$14,103in general payments, 2019–2025

Across 580 payments — averaging $24.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$2K
  • OPKO Pharmaceuticals, LLC$1K
  • Vifor Pharma, Inc.$1K
  • AstraZeneca$1K
  • Amgen$1K
  • Travere Therapeutics, Inc.$891
  • plus $6K from 30 others

What the payments were for

  • Food & beverage$13,54996%
  • Education$5554%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,103 in reported general payments places this provider in the 85th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$409,318
Medicare patients
652
Services billed
4,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FilspariSparsentan14$152,639
XphozahTenapanor Hcl43$137,666
FarxigaDapagliflozin Propanediol69$71,114
RayaldeeCalcifediol39$60,460
VeltassaPatiromer Calcium Sorbitex28$37,622
LokelmaSodium Zirconium Cyclosilicate31$26,419
ProsolParenteral Amino Acid 20% No.167$10,623
Sevelamer Carbonate31$6,191
Calcitriol401$5,677
Allopurinol254$3,181
Torsemide162$2,342
Cinacalcet Hcl15$1,474
Losartan Potassium120$1,240
Calcium Acetate21$1,045
Potassium Chloride44$811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Travere Therapeutics, Inc.Filspari$891$152,63914 claims
AstraZenecaFarxiga, Lokelma$1,336$97,534100 claims
OPKO Pharmaceuticals, LLCRayaldee$1,485$60,46039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 524 nephrology providers in Illinois.

Other nephrology in Kankakee

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →